Journal of Community Nursing - page 5

Efficacy proven even in heavy smokers (27 cpd, 3 previous
quit attempts)
1
94% more effective at helping smokers quit compared with
placebo at 12 weeks
(34% on NICORETTE
®
Invisi 25mg Patch vs. 17.5%
on placebo; p<0.001)
2
Designed to mimic your patients’ regular smoking pattern
by avoiding nocturnal nicotine dosing
NICORETTE
®
Invisi Patch Prescribing Information:
Presentation:
Transdermal delivery system available in 3 sizes (22.5, 13.5 and 9cm
2
)
releasing 25mg, 15mg and 10mg of nicotine respectively over 16 hours.
Uses:
NICORETTE
®
Invisi Patch relieves and/or prevents craving and nicotine withdrawal
symptoms associated with tobacco dependence. It is indicated to aid smokers wishing
to quit or reduce prior to quitting, to assist smokers who are unwilling or unable to
smoke, and as a safer alternative to smoking for smokers and those around them.
NICORETTE
®
Invisi Patch is indicated in pregnant and lactating women making a quit
attempt. If possible, NICORETTE
®
Invisi Patch should be used in conjunction with a
behavioural support programme.
Dosage:
It is intended that the patch is worn through
the waking hours (approximately 16 hours) being applied on waking and removed at
bedtime.
Smoking Cessation: Adults (over 18 years of age):
For best results, most
smokers are recommended to start on 25mg/16 hours patch (Step 1) and use one patch
daily for 8 weeks. Gradual weaning from the patch should then be initiated. One
15mg/16 hours patch (Step 2) should be used daily for 2 weeks followed by one
10mg/16 hours patch (Step 3) daily for 2 weeks.Lighter smokers (i.e. those who smoke
less than 10 cigarettes per day) are recommended to start at Step 2 (15mg) for 8 weeks
and decrease the dose to 10mg for the final 4 weeks.Those who experience excessive
side effects with the 25mg patch (Step 1), which do not resolve within a few days,
should change to a 15mg patch (Step 2). This should be continued for the remainder
of the 8 week course, before stepping down to the 10mg patch (Step 3) for 4 weeks.
If symptoms persist the advice of a healthcare professional should be sought.
Adolescents (12 to 18 years):
Dose and method of use are as for adults however,
recommended treatment duration is 12 weeks. If longer treatment is required, advice
from a healthcare professional should be sought.
Smoking Reduction/Pre-Quit:
Smokers are recommended to use the patch to prolong smoke-free intervals and with
the intention to reduce smoking as much as possible. Starting dose should follow the
smoking cessation instructions above i.e.25mg (Step 1) is suitable for those who smoke
10 or more cigarettes per day and for lighter smokers are recommended to start at
Step 2 (15mg).Smokers starting on 25mg patch should transfer to 15mg patch as soon
as cigarette consumption reduces to less than 10 cigarettes per day. A quit attempt
should be made as soon as the smoker feels ready. When making a quit attempt
smokers who have reduced to less than 10 cigarettes per day are recommended to
continue at Step 2 (15mg) for 8 weeks and decrease the dose to 10mg (Step 3) for
the final 4 weeks.
Temporary Abstinence:
Use a NICORETTE
®
Invisi Patch in those
situations when you can’t or do not want to smoke for prolonged periods (greater than
16 hours). For shorter periods then an alternative intermittent dose form would be more
suitable (e.g. NICORETTE
®
inhalator or gum). Smokers of 10 or more cigarettes per day
are recommended to use 25mg patch and lighter smokers are recommended to use
15mgpatch.
Contraindications:
Hypersensitivity.
Precautions:
Unstablecardiovascular
disease, diabetes mellitus, renal or hepatic impairment, phaeochromocytoma or
uncontrolled hyperthyroidism, generalised dermatological disorders.Angioedema and
urticaria have been reported. Erythema may occur. If severe or persistent, discontinue
treatment. Stopping smoking may alter the metabolism of certain drugs. Transferred
dependence is rare and less harmful and easier to break than smoking dependence.
May enhance the haemodynamic effects of, and pain response, to adenosine. Keep out
of reach and sight of children and dispose of with care.
Pregnancy and lactation:
Only after consulting a healthcare professional.
Side effects:
Very common:
itching.
Common:
headache, dizziness, nausea, vomiting, GI discomfort; Erythema.
Uncommon:
palpitations, urticaria.
Very rare:
reversible atrial fibrillation. See SPC for further details.
NHS Cost:
25mg packs of 7: (£9.97); 25mg packs of 14: (£16.35); 15mg packs of 7:
(£9.97); 10mg packs of 7: (£9.97).
Legal category:
GSL.
PL holder:
McNeil Products
Ltd, Roxborough Way, Maidenhead, Berkshire, SL6 3UG.
PL numbers:
15513/0161;
15513/0160; 15513/0159.
Date of preparation:
Feb 2012
Adverse events should be reported. Reporting forms and
information can be found at
Adverse events should also be reported to McNeil
Products Limited on 01344 864 042.
Reference:1.
TønnesenP
etal.EurRespJ
1999;
13:
238–246.
2.
Dataonfile–CEASE4.
Date of preparation:
August 2013
UK/NI/12-1003a
“ I used to be stuck on smoking.
With NICORETTE
®
Invisi 25mg Patch,
I’m sticking with quitting”
nicotine
Designed
to help your
smokers quit for good
1,2,3,4 6,7,8,9,10,11,12,13,14,15,...116